Meeting
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Evan Y. Yu
Seattle Cancer Care Alliance, Seattle, WA
Evan Y. Yu , Haiyan Wu , Charles Schloss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02861573
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5089)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5089
Abstract #
TPS5089
Poster Bd #
161b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
First Author: Charles J. Ryan